Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 5/20 | 0.74 |
| ▸ | GAA | P10253 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 5/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.74 |
| ▸ | NPC1 | O15118 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | APP | P05067 | 16/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31219369 | 1.00 | GLA (0.74) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL8530650 | 0.91 | APP (0.74) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL6854930 | 0.87 | MAPT (0.96) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL1995933 | 0.86 | MAPT (1.00) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL2628263 | 0.84 | APP (1.00) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL1727124 | 0.84 | APP (1.00) | GLAGAAMAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL38731 | 0.82 | APP (0.97) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL13354675 | 0.82 | APP (0.72) | GLAGAAMAPTKDM4ENPC1 | |
| SCHEMBL21752044 | 0.82 | APP (1.00) | GLAGAAMAPTAPP | |
| SCHEMBL11994274 | 0.82 | APP (0.72) | GLAGAAMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-15 | — | — | US | disclosed |
| CN-113727972-A | Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof | 韩国科学技术研究院 | 2021-11-30 | — | — | CN | disclosed |
| EP-3901139-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | Korea Institute of Science and Technology (KR) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020130214-A1 | NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF | 한국과학기술연구원 | 2020-06-25 | — | — | WO | disclosed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-17 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC | 2010-06-10 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700616-B2 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. (US) | 2010-04-20 | — | — | US | disclosed |
| WO-2008118122-A2 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | MOLECULAR NEUROIMAGING, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | MOLECULAR NEUROIMAGING, LLC. | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258887-A1 | Compounds and amyloid probes thereof for therapeutic and imaging uses | APP, BACE1, BACE2 | GLA 623/4885GAA 749/4885MAPT 29/4885 |
| US-20100143253-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | GLA 623/4885GAA 749/4885MAPT 29/4885 |
| US-20100150833-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | GLA 623/4885GAA 749/4885MAPT 29/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | GLA 3136/4885GAA 3766/4885MAPT 3633/4885 |
| US-20100143251-A1 | COMPOUNDS AND AMYLOID PROBES THEREOF FOR THERAPEUTIC AND IMAGING USES | APP, BACE1, BACE2 | GLA 623/4885GAA 749/4885MAPT 29/4885 |
| US-20220396553-A1 | NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF | AANAT, NAT1, HNMT | GLA 3622/4885GAA 3976/4885MAPT 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.